The Standard Concentration of Morphine as a Positive Control for Intradermal Skin Test
NCT ID: NCT00853476
Last Updated: 2011-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2009-03-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases
NCT04937101
Inter-arm and Inter-period Reproducability of the Dermal Blood Flow Response After a Histamine Skin Prick.
NCT04396977
To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects
NCT07109453
Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Skin Prick Test Positive Control
NCT02561429
Role of Skin Tests for the Diagnosis of Immediate Hypersensitivity Reactions Due to Iodinated Contrast Media
NCT00819494
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* cancer
* severe skin diseases
* severe medical illnesses
* malnutrition
* uncontrolled asthma
* pregnancy
* received oral or systemic corticosteroid within 1 month before this study
* receiving immunosuppressive agents
* taken antihistamine within 3 days before this study
* taking beta-blocker
* previous history of immunotherapy
* have hypersensitivity reaction to morphine/opiates
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chulalongkorn University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jettanong Klaewsongkram, MD
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Chulalongkorn University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Chula-ARC 001/09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.